{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:27:10Z","timestamp":1788798430566,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.urolonc.2018.02.002","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T18:28:28Z","timestamp":1520274508000},"page":"242.e9-242.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette-Guerin response in nonmuscle invasive bladder cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Islam M.","family":"El-Babouly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esam A.E.","family":"Desoky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diab","family":"El Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola A.","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr M.","family":"Fawzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashaat M.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim I.","family":"Samaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2018.02.002_bib1","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2018.02.002_bib2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","article-title":"History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story","volume":"179","author":"Herr","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib5","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2018.02.002_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.urolonc.2013.06.008","article-title":"Predicting response to bacillus Calmette-Gu\u00e9rin (BCG) in patients with carcinoma in situ of the bladder","volume":"32","author":"Nunez-Nateras","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib7","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-5347(01)69072-4","article-title":"Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year follow up","volume":"167","author":"Davis","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib9","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1097\/01.ju.0000181799.81119.fc","article-title":"Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy","volume":"174","author":"Herr","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.juro.2006.08.070","article-title":"Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?","volume":"177","author":"Herr","year":"2007","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2018.02.002_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neulet.2012.08.044","article-title":"NEDD9 rs760678 polymorphism and the risk of Alzheimer\u2019s disease: a meta-analysis","volume":"527","author":"Wang","year":"2012","journal-title":"Neur Sci Lett"},{"key":"10.1016\/j.urolonc.2018.02.002_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/6095205","article-title":"The prognostic role of NEDD9 and P38 protein expression levels in urinary bladder transitional cell carcinoma","volume":"2017","author":"Harb","year":"2017","journal-title":"J Oncol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib13","series-title":"TNM classification of malignant tumors (UICC International Union Against Cancer)","first-page":"262","author":"Sobin","year":"2009"},{"key":"10.1016\/j.urolonc.2018.02.002_bib14","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.eururo.2006.10.037","article-title":"Histologic grading of noninvasive papillary urothelial neoplasms","volume":"51","author":"MacLennan","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/29.4.6166661","article-title":"Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures","volume":"29","author":"Hsu","year":"1981","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.urolonc.2018.02.002_bib16","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/sj.onc.1209199","article-title":"HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells","volume":"25","author":"Natarajan","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2018.02.002_bib17","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1038\/onc.2010.632","article-title":"HEF1, a novel target of Wnt signaling, promotes colonic cell migration and cancer progression","volume":"30","author":"Li","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2018.02.002_bib18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib19","first-page":"433","article-title":"Albert Calmette (1863\u20131933): originator of the BCG vaccine","volume":"53","author":"Tan","year":"2012","journal-title":"Singapore Med J"},{"key":"10.1016\/j.urolonc.2018.02.002_bib20","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2008.11.019","article-title":"Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed","volume":"181","author":"Morales","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib22","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1464-410X.2011.10462.x","article-title":"Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?","volume":"109","author":"Segal","year":"2011","journal-title":"BJUI"},{"key":"10.1016\/j.urolonc.2018.02.002_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1078-1439(03)00144-3","article-title":"Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy","volume":"22","author":"Bianco","year":"2004","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"6","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib25","doi-asserted-by":"crossref","first-page":"e96671","DOI":"10.1371\/journal.pone.0096671","article-title":"Platelet-derived growth factor receptor beta: a novel urinary biomarker for recurrence of non-muscle-invasive bladder cancer","volume":"9","author":"Feng","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2018.02.002_bib26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/00005392-200102000-00005","article-title":"Human complement factor H related protein test for monitoring bladder cancer","volume":"165","author":"Raitanen","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.02.002_bib27","first-page":"170","article-title":"miR-145-mediated suppression of cell growth, invasion and metastasis","volume":"2","author":"Sachdeva","year":"2010","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.urolonc.2018.02.002_bib28","first-page":"31","article-title":"Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder","volume":"36","author":"Kibar","year":"2006","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.urolonc.2018.02.002_bib29","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/1078-0432.CCR-08-1143","article-title":"Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression","volume":"15","author":"Feldman","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2018.02.002_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3233\/BLC-160054","article-title":"A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer","volume":"2","author":"D\u2019Costaa","year":"2016","journal-title":"Bladder Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918300425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918300425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:13:00Z","timestamp":1761041580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143918300425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1078143918300425"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.02.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette-Guerin response in nonmuscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}